The National Institute for Health and Care Excellence (NICE) has been asked to conduct an evaluation of apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency.
We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal.
Following an update from the company responsible for apadamtase alfa, NICE will not be progressing with this scoping exercise and the workshop arranged for Friday 13 March 2026 has been cancelled. Please accept our apologies for any inconvenience at this late stage.
As this evaluation has been referred to NICE, we will continue dialogue with the company and will update interested parties if the situation changes.